Romosozumab in severe postmenopausal osteoporosis—real-world data from 192 women
Authors' conclusion
Our real-world data corroborate the results from controlled studies and provide new insights into microstructural changes as well as biochemical treatment monitoring.
Study context
- Population
- Postmenopausal women with severe osteoporosis treated with romosozumab, 2020 to 2024
- Participants
- 192 women
- Exposure
- Treatment-naïve (TN) vs antiresorptive (AR)
- Outcome
- Change in aBMD with romosozumab
Methodological detailsreal-world, single-centre
- Real-world
- Single-centre
Main finding
As reported in the abstract
- Lumbar spine areal bone mineral density (aBMD) change, 14.47 ± 8.74%
- p < 0.001
- Total hip aBMD change, 4.15 ± 5.92%
- p < 0.001
Observational data: associations, not effects.
Further findings
Lumbar spine aBMD change by previous treatment
P < 0.001
Bone formation and trabecular microarchitecture
- Increase in bone formation parameters after 6 months and in trabecular microarchitectural parameters (high-resolution peripheral quantitative computed tomography (HR-pQCT)) at 12 months; changes significantly lower with previous bone specific treatment
Original publication
Romosozumab in severe postmenopausal osteoporosis—real-world data from 192 women. Osteoporos Int. Published 8 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →